Celastrol suppresses humoral immune responses and autoimmunity by targeting the COMMD3/8 complex.
Taiichiro ShiraiAkiko NakaiEmiko AndoJun FujimotoSarah LeachTakao ArimoriDaisuke HigoFloris J van EerdenJanyerkye TulyeuYu-Chen LiuDaisuke OkuzakiMasanori A MurayamaHaruhiko MiyataKazuto NunomuraBangzhong LinAkiyoshi TaniAtsushi KumanogohMasahito IkawaJames Badger WingDaron M StandleyJunichi TakagiKazuhiro SuzukiPublished in: Science immunology (2023)
Celastrol, a bioactive molecule extracted from the Tripterygium wilfordii plant, has been shown to exhibit anti-inflammatory properties. However, its mechanism of action has not been fully elucidated. Here, we show that celastrol suppresses humoral immune responses and autoimmunity by disabling a protein complex consisting of copper metabolism MURR1 domain-containing (COMMD) 3 and COMMD8 (COMMD3/8 complex), a signaling adaptor for chemoattractant receptors. Having demonstrated the involvement of the COMMD3/8 complex in a mouse model of rheumatoid arthritis, we identified celastrol as a compound that covalently bound to and dissociated the COMMD3/8 complex. Celastrol inhibited B cell migration, reduced antibody responses, and blocked arthritis progression, recapitulating deficiency of the COMMD3/8 complex. These effects of celastrol were abolished in mice expressing a celastrol-resistant mutant of the COMMD3/8 complex. These findings establish that celastrol exerts immunosuppressive activity by targeting the COMMD3/8 complex. Our study suggests that the COMMD3/8 complex is a potentially druggable target in autoimmune diseases and points to celastrol as a lead pharmacologic candidate in this capacity.